Levokast Oral Suspension is a combination medication containing Levocetirizine dihydrochloride (2.5 mg/5 ml) and Montelukast sodium (4 mg/5 ml), formulated for the management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively antagonizes peripheral H1 receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene D4 at the CysLT1 receptor, reducing bronchoconstriction, inflammation, and mucus production in the airways. The synergistic action of these agents provides comprehensive relief from allergic manifestations, including seasonal and perennial allergic rhinitis, and asthma prophylaxis in pediatric and adult patients. Levokast Oral Suspension is particularly beneficial in patients who require both antihistaminic and anti-leukotriene therapy for optimal symptom control. The oral suspension form facilitates ease of administration and dose adjustment, especially in pediatric populations. It is generally well tolerated, with a low incidence of adverse effects such as headache, somnolence, and gastrointestinal disturbances. Levokast should be used under medical supervision, with consideration for contraindications and potential drug interactions.